2009
DOI: 10.1177/1758834009347323
|View full text |Cite
|
Sign up to set email alerts
|

Review: Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers

Abstract: Pre-and peri-operative strategies are becoming standard for the management of localized gastro-esophageal cancer. For localized gastric/gastro-esophageal junction (GEJ) cancer there are conflicting data that a peri-operative approach with cisplatin-based chemotherapy improves survival, with the benefits seen in esophageal cancer likely less than a 510% incremental improvement. Further trends toward improvement in local control and survival, when combined chemotherapy and radiation therapy are given pre-operati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2012
2012
2024
2024

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(1 citation statement)
references
References 123 publications
0
1
0
Order By: Relevance
“…Residual disease can be considered a factor linked to aggressive, CRT-resistant disease with a higher potential for metastasis (61)(62)(63)(64). Therefore, a reliable diagnostic test allowing prediction of response is necessary for the future use of preoperative chemotherapy in patients with esophageal cancer (65). Recent evidence suggests a promising role for positron emission tomography (PET) with radiolabelled fluorodeoxyglucose (FDG) for prediction of response during the early phase of chemotherapy.…”
Section: Prediction Of Responsementioning
confidence: 99%
“…Residual disease can be considered a factor linked to aggressive, CRT-resistant disease with a higher potential for metastasis (61)(62)(63)(64). Therefore, a reliable diagnostic test allowing prediction of response is necessary for the future use of preoperative chemotherapy in patients with esophageal cancer (65). Recent evidence suggests a promising role for positron emission tomography (PET) with radiolabelled fluorodeoxyglucose (FDG) for prediction of response during the early phase of chemotherapy.…”
Section: Prediction Of Responsementioning
confidence: 99%